Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046927 | 0.91 | POLB (0.45) | HTTSHMT2TSHRPOLBTRPV4 | |
| SCHEMBL13046920 | 0.91 | HTT (0.52) | HTTP2RX7APOBEC3AAPOBEC3GUSP2 | |
| SCHEMBL13046926 | 0.89 | KMT2A (0.44) | HTTSHMT2MAPK1TSHRPOLB | |
| SCHEMBL13046914 | 0.88 | HTT (0.52) | HTTSHMT2MAPK1POLBCNR2 | |
| SCHEMBL13046993 | 0.87 | RXFP1 (0.45) | HTTSHMT2MAPK1POLBL3MBTL1 | |
| SCHEMBL13047030 | 0.86 | HTT (0.48) | HTTSHMT2TSHRPOLBTRPV4 | |
| SCHEMBL13046976 | 0.86 | HTT (0.50) | HTTSHMT2TSHRPOLBTRPV4 | |
| SCHEMBL13047039 | 0.85 | SMN1; SMN2 (0.45) | HTTP2RX7SHMT2TSHRPOLB | |
| SCHEMBL13046916 | 0.85 | HTT (0.61) | HTTP2RX7 | |
| SCHEMBL13046936 | 0.85 | ALDH1A1 (0.53) | SHMT2TSHRAPOBEC3AAPOBEC3GPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | HTT 4422/4885P2RX7 1/4885SHMT2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.